Results 251 to 260 of about 80,266 (330)

Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.

Blood
Brown JR, Nguyen B, Desikan SP, Won H, Tantawy SI, McNeely SC, Marella N, Randeria HS, Hanson LM, Parker A, Botelho SC, Woyach JA, Patel K, Tam CS, Eyre TA, Cheah CY, Shah NN, Ghia P, Jurczak W, Balbas M, Nair B, Abada P, Wang C, Wang D, Roeker LE, Gandhi V, Wierda WG.   +26 more
europepmc   +1 more source

Microsecond simulations to investigate the structural mechanism of super-resistant double mutations in BTK to the covalent inhibitor ibrutinib in multiple leukemia. [PDF]

Sci Rep
Khan A, Ali SS, Zahid MA, Alshabrmi FM, Al-Zoubi RM, Shkoor M, Mohammmad A, Wei DQ, Agouni A.   +8 more
europepmc   +1 more source

BTK inhibitor TG-1701 [PDF]

, 2020
openaire   +1 more source

Bruton Tyrosine Kinase Inhibition Limits Multiple Sclerosis Disease-Driving Inflammation While Promoting Regulatory B Cells. [PDF]

Neurol Neuroimmunol Neuroinflamm
Dybowski S, Thode J, Freier M, Saberi D, Nessler S, Geladaris A, Häusser-Kinzel S, Ringelstein M, Torke S, Weber MS.   +9 more
europepmc   +1 more source

First-line treatment for CLL in the era of targeted therapy. [PDF]

Blood Cancer J
Davids MS, Stilgenbauer S, Tam CS.
europepmc   +1 more source

Discovery ofImidazo[1,2‑b]pyridazine Derivatives as Potentand Highly Selective IrreversibleBruton’s Tyrosine Kinase (BTK) Inhibitors

Dandan Zhang (228849), Jie Zhao (49409), Guiqing Xu (148569), Yue Wang (65477), Yang Li (7082), Hanxiao Ren (21367266), Jiajun Geng (21367269), Yu Du (618167), Chenchen Zhang (324804), Shouning Yang (8656365), Dongfang Liu (241581), Jiajing Gao (21096485), Yi Xiong (142047), Haoyi Zhang (2325214), Wei Li (7081), Wei Wang (17594), Di Wang (329735), Biao Li (36684), Xing He (614068), Chunhua Ma (5792261), Yuqin Jiang (6618434), Qingjie Ding (1846105)   +21 more
openalex   +1 more source

The Precision Revolution in Hematologic Malignancies: A Decade of Transformative Immunotherapies and Targeted Agents. [PDF]

J Clin Med
Mansour GK, Hajjar AW, Sajid MR.
europepmc   +1 more source

Integrating Network Pharmacology and Experimental Validation to Investigate the Action Mechanism of Allicin in Atherosclerosis. [PDF]

Drug Des Devel Ther
Wu S, Liu T, Weng M, Zhou Y, Ye L, Ruan S, Tang D, Zhong Q, Liu L, Zhao G.   +9 more
europepmc   +1 more source

Rilzabrutinib in immune thrombocytopenia: a targeted, patient-centered alternative to conventional therapies. [PDF]

Ann Med Surg (Lond)
Afridi H, Qazi K, Rizvi MA, Nasir R, Mahato RK.   +4 more
europepmc   +1 more source